Both in Pharmaceuticals
Protagonist Therapeutics vs Arrowhead Research
Over the past year PTGX returned +87.4% and ARWR returned +62.9%; their daily moves had a correlation of 0.33.
PTGX +87.4% ARWR +62.9%Growth of $1, one year, split-adjusted
| Metric | PTGX | ARWR |
|---|---|---|
| Price | $143.37 | $61.65 |
| Market cap | $9.28B | $8.71B |
| Today | +2.23% | +3.56% |
| 1 month | +3.4% | +0.2% |
| 6 months | +37.9% | −22.1% |
| Year to date | +64.2% | −7.1% |
| 1 year | +88.8% | +55.6% |
| Revenue growth (YoY) | +3749.2% | +171.0% |
| Gross margin | 100.0% | 100.0% |
| Net margin | 76.3% | −258.2% |
| P/E (TTM) | 111.9× | — |
| Price / sales | 32.9× | 13.0× |
| Net cash | $782.6M | $737.9M |
| Dividend yield | — | — |
| Volatility (60d) | 32.0% | 45.8% |
| Short % of float | 16.8% | 8.1% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).